Valuation: Polaris Group

Market Cap 11.31B 354M 310M 285M 265M 502M 33.81B 513M 3.43B 1.33B 16.55B 1.33B 1.3B 57.15B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 11.82B 371M 324M 298M 277M 525M 35.35B 536M 3.58B 1.39B 17.31B 1.39B 1.36B 59.76B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
34.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.87%
1 week-2.95%
Current month-2.95%
1 month+0.38%
3 months-35.22%
6 months-57.72%
Current year-57.72%
1 week 12.5
Extreme 12.5
14.35
1 month 12.5
Extreme 12.5
14.35
Current year 12.5
Extreme 12.5
35.95
1 year 12.5
Extreme 12.5
44.55
3 years 12.5
Extreme 12.5
91.1
5 years 12.5
Extreme 12.5
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Director/Board Member 78 -
Chairman 64 2014-11-23
Director/Board Member 75 2020-02-24
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%-2.95%-66.96%-83.88% 362M
+0.36%+6.85%+0.11%+5.85% 48.62B
+0.92%+11.47%+412.98%+607.44% 39.86B
+1.89%+11.54%+27.32%-7.89% 33.91B
+2.38%+7.41%+21.41%+66.94% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+2.51%+15.33% - - 16.63B
+2.58%+8.74%+73.67%+132.17% 15.52B
+0.99%+3.16%+13.75%+18.88% 13.63B
-1.14%+9.41%+16.24%-30.83% 13.41B
Average +0.90%+7.43%+57.13%+82.34% 23.9B
Weighted average by Cap. +1.13%+7.72%+89.93%+130.69%

Financials

2024 2025
Net sales 107M 3.35M 2.93M 2.69M 2.51M 4.75M 320M 4.85M 32.41M 12.56M 157M 12.59M 12.32M 541M 40.6M 1.27M 1.11M 1.02M 952K 1.8M 121M 1.84M 12.3M 4.77M 59.44M 4.78M 4.67M 205M
Net income -2.5B -78.44M -68.56M -62.98M -58.71M -111M -7.48B -113M -758M -294M -3.66B -295M -288M -12.65B -3.93B -123M -108M -98.83M -92.13M -174M -11.74B -178M -1.19B -461M -5.75B -462M -452M -19.85B
Net Debt 9.19M 288K 252K 231K 216K 408K 27.48M 417K 2.78M 1.08M 13.46M 1.08M 1.06M 46.46M 517M 16.2M 14.16M 13.01M 12.13M 22.95M 1.55B 23.43M 157M 60.68M 757M 60.83M 59.5M 2.61B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
26-07-02 NT$13.15 -1.87% 1,160,519
26-07-01 NT$13.40 -1.11% 1,872,902
26-06-30 NT$13.55 +2.26% 1,274,774
26-06-29 NT$13.25 +6.00% 1,513,600
26-06-26 NT$12.50 -4.21% 2,171,938
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock